|
TXNDC16 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.70785607878088E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.71385128311385E-12 |
| Normal-vs-Stage2 |
1.06048503312195E-12 |
| Normal-vs-Stage3 |
2.23521201547783E-12 |
| Normal-vs-Stage4 |
5.60995694343092E-13 |
| Stage1-vs-Stage2 |
7.472800E-01 |
| Stage1-vs-Stage3 |
7.581600E-01 |
| Stage1-vs-Stage4 |
5.783600E-01 |
| Stage2-vs-Stage3 |
6.428800E-01 |
| Stage2-vs-Stage4 |
8.659800E-01 |
| Stage3-vs-Stage4 |
5.157200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.55981951985996E-14 |
| Normal-vs-AfricanAmerican |
3.35870000001126E-06 |
| Normal-vs-Asian |
5.86308779304545E-13 |
| Caucasian-vs-AfricanAmerican |
3.132400E-01 |
| Caucasian-vs-Asian |
7.777600E-01 |
| AfricanAmerican-vs-Asian |
2.841800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.67099667436332E-12 |
| Normal-vs-Female |
1.74904535299447E-12 |
| Male-vs-Female |
5.061200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.88593585193075E-12 |
| Normal-vs-Age(41-60Yrs) |
1.63191682389652E-12 |
| Normal-vs-Age(61-80Yrs) |
7.4797945615046E-12 |
| Normal-vs-Age(81-100Yrs) |
1.520060E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.550200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.661800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.395000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.240400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.096000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.681200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.224600E-01 |
| Classical-VS-Follicular |
4.493000E-01 |
| Classical-VS-Other |
3.713200E-01 |
| Classical-VS-Normal |
9.44244682443696E-13 |
| Tall-VS-Follicular |
7.388600E-01 |
| Tall-VS-Other |
4.243400E-01 |
| Tall-VS-Normal |
1.14850018384516E-10 |
| Follicular-VS-Other |
5.893000E-01 |
| Follicular-VS-Normal |
2.34001706900244E-12 |
| Other-VS-Normal |
2.002800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.02695629777827E-13 |
| Normal-vs-N1 |
1.65578661892596E-12 |
| N0-vs-N1 |
2.103000E-01 |
|
|
